摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氟-4-三氟甲氧基苯硼酸 | 503309-10-2

中文名称
2-氟-4-三氟甲氧基苯硼酸
中文别名
——
英文名称
(2-fluoro-4-(trifluoromethoxy)phenyl)boronic acid
英文别名
[2-fluoro-4-(trifluoromethoxy)phenyl]boronic acid
2-氟-4-三氟甲氧基苯硼酸化学式
CAS
503309-10-2
化学式
C7H5BF4O3
mdl
——
分子量
223.92
InChiKey
YQMMVZVQAHYXFZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    114-116 °C(Solv: pentane (109-66-0))
  • 沸点:
    244.2±50.0 °C(Predicted)
  • 密度:
    1.48±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    49.7
  • 氢给体数:
    2
  • 氢受体数:
    7

安全信息

  • 海关编码:
    2931900090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:91bbb7b0eb1c937a05ddf78ea1efc8cb
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Fluoro-4-trifluoromethoxyphenylboronic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-4-trifluoromethoxyphenylboronic acid
CAS number: 503309-10-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BF4O3
Molecular weight: 223.9

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-氟-4-三氟甲氧基苯硼酸platinum(IV) oxide四(三苯基膦)钯氢气碳酸氢钠 、 magnesium sulfate 、 三乙胺 作用下, 以 乙二醇二甲醚乙醇 为溶剂, 生成 (-)-1-methyl-(2-((cis-3-methyl-4-(4-trifluoromethyl-2-fluoro)phenyl)piperidin-1-yl)methyl)-1H-imidazo[ 4,5-b]pyridine
    参考文献:
    名称:
    1-[(1-Methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 Positive Allosteric Modulators for the Treatment of Psychosis
    摘要:
    A novel series of mGluR2 positive allosteric modulators (PAMs), 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines, is herein disclosed. Structure-activity relationship studies led to potent, selective mGluR2 PAMs with excellent pharmacokinetic profiles. A representative lead compound (+)-17e demonstrated dose-dependent inhibition of methamphetamine-induced hyperactivity and mescaline-induced scratching in mice, providing support for potential efficacy in treating psychosis.
    DOI:
    10.1021/jm101414h
  • 作为产物:
    描述:
    1-溴-2-氟-4-三氟甲氧基苯正丁基锂硼酸三异丙酯盐酸 作用下, 以 四氢呋喃正己烷甲苯 为溶剂, 反应 7.17h, 以75%的产率得到2-氟-4-三氟甲氧基苯硼酸
    参考文献:
    名称:
    Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
    摘要:
    New heterocyclic analogues of the potent biphenyl class derived from antitubercular drug PA-824 were prepared, aiming to improve aqueous solubility but maintain high metabolic stability and efficacy. The strategy involved replacement of one or both phenyl groups by pyridine, pyridazine, pyrazine, or pyrimidine, in order to reduce lipophilicity. For para-linked biaryls, hydrophilicities (ClogP) correlated with measured solubilities, but highly soluble bipyridine analogues displayed weak antitubercular activities. A terminal pyridine or proximal heterocycle allowed retention of potency and provided solubility improvements, particularly at low pH, with examples from the latter classes displaying the better in vivo efficacies, high metabolic stabilities, and excellent pharmacokinetics. Five such compounds were >100-fold better than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection, and two orally bioavailable pyridine analogues (3-4-fold more soluble than the parent at low pH) were superior to antitubercular drug OPC-67683 in a chronic infection model.
    DOI:
    10.1021/jm101288t
点击查看最新优质反应信息

文献信息

  • C(acyl)–C(sp<sup>2</sup>) and C(sp<sup>2</sup>)–C(sp<sup>2</sup>) Suzuki–Miyaura cross-coupling reactions using nitrile-functionalized NHC palladium complexes
    作者:Sinem Çakır、Serdar Batıkan Kavukcu、Hande Karabıyık、Senthil Rethinam、Hayati Türkmen
    DOI:10.1039/d1ra07231e
    日期:——
    N-heterocyclic carbene (NHC) palladium complexes has been successful for the modulation of C–C coupling reactions. For this purpose, a series of azolium salts (1a–f) including benzothiazolium, benzimidazolium, and imidazolium, bearing a CN-substituted benzyl moiety, and their (NHC)2PdBr2 (2a–c) and PEPPSI-type palladium (3b–f) complexes have been systematically prepared to catalyse acylative Suzuki–Miyaura
    N-杂环卡宾(NHC)钯配合物的应用已成功用于调节C-C偶联反应。为此,包括苯并噻唑鎓、苯并咪唑鎓和咪唑鎓在内的一系列唑鎓盐 ( 1a-f ),带有 CN 取代的苄基部分,以及它们的 (NHC) 2 PdBr 2 ( 2a-c ) 和 PEPPSI 型钯 ( 3b -F) 已系统地制备了配合物以催化酰氯与芳基硼酸的酰化 Suzuki-Miyaura 偶联反应,在碳酸钾作为碱存在下形成二苯甲酮衍生物,并催化溴苯与芳基硼酸的传统 Suzuki-Miyaura 偶联反应形成联芳基。所有合成的化合物均通过傅里叶变换红外 (FTIR) 和1 H 和13 C NMR 光谱进行了充分表征。3c、3e和3f单晶的X射线衍射研究证明正方形平面几何。进行了扫描电子显微镜 (SEM)、能量色散 X 射线光谱 (EDS)、金属映射分析和热重分析 (TGA),以进一步了解 Suzuki-Miyaura 交叉偶联反应的机制。机理研究表明,CN
  • Insecticial 3-(2,6-disubstituted phenyl)-5-[4- or 5-arylthien-2- or -3-yl]-1,2,4-triazoles
    申请人:——
    公开号:US20030134748A1
    公开(公告)日:2003-07-17
    Triazole compounds having a 2,6-disubstituted-phenyl group in the 3-position, arylthien-2- or -3-yl in the 5-position and an alkyl group in the 1-position are effective in controlling lepidoptera, coleoptera, mites and other sucking pests.
    三唑类化合物,在3位具有2,6-二取代苯基,5位为芳基噻吩-2-或-3-基团,1位为烷基基团,对于控制鳞翅目、鞘翅目、螨类和其他吸食性害虫具有有效性。
  • Novel Cyclopropabenzofuranyl Pyridopyrazinediones
    申请人:Pfizer Inc.
    公开号:US20160222007A1
    公开(公告)日:2016-08-04
    Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R 1 , R 2a , R 2b , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 10 , R 11 , and y are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    揭示了化合物及其在药学上可接受的盐,其中该化合物具有Formula I的结构 其中X,R 1 ,R 2a ,R 2b ,R 4a ,R 4b ,R 5a ,R 5b ,R 6 ,R 7 ,R 10 ,R 11 和y如规范中所定义。还公开了相应的药物组合物、治疗方法、合成方法和中间体。
  • Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis
    申请人:Arrien Pharmaceuticals LLC
    公开号:US20150072980A1
    公开(公告)日:2015-03-12
    The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.
    本发明涉及化合物、它们的合成以及它们作为Retinoic acid-related orphan核受体γt (RORγt)/RORγ的拮抗剂、逆向激动剂、调节剂和/或抑制剂的用途。本发明的化合物对调节RORγt)/RORγ活性以及治疗由RORγt)/RORγ介导的疾病或病况具有用处,例如与人类自身免疫疾病的免疫病理学相关的疾病状态,如多发性硬化症(MS)、类风湿关节炎(RA)、炎症性结肠炎、牛皮癣、慢性阻塞性肺病(COPD)、疼痛、肥胖、糖尿病、血脂异常、骨质疏松症、哮喘、神经退行性疾病和癌症。
  • 화합물 및 이를 이용한 유기발광소자
    申请人:LG CHEM, LTD. 주식회사 엘지화학(120010134563) Corp. No ▼ 110111-2207995BRN ▼107-81-98139
    公开号:KR20170094708A
    公开(公告)日:2017-08-21
    본 명세서는 화합물 및 이를 포함하는 유기 발광 소자를 제공한다.
    这份规范提供了化合物和含有它们的有机发光元件。
查看更多